405 related articles for article (PubMed ID: 29633255)
1. HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells.
Cao C; Wu H; Vasilatos SN; Chandran U; Qin Y; Wan Y; Oesterreich S; Davidson NE; Huang Y
Int J Cancer; 2018 Sep; 143(6):1388-1401. PubMed ID: 29633255
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells.
Vasilatos SN; Katz TA; Oesterreich S; Wan Y; Davidson NE; Huang Y
Carcinogenesis; 2013 Jun; 34(6):1196-207. PubMed ID: 23354309
[TBL] [Abstract][Full Text] [Related]
3. Functional interaction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression.
Cao C; Vasilatos SN; Bhargava R; Fine JL; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2017 Jan; 36(1):133-145. PubMed ID: 27212032
[TBL] [Abstract][Full Text] [Related]
4. Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
Yang F; Wang F; Liu Y; Wang S; Li X; Huang Y; Xia Y; Cao C
Life Sci; 2018 Nov; 213():149-157. PubMed ID: 30352240
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells.
Huang Y; Vasilatos SN; Boric L; Shaw PG; Davidson NE
Breast Cancer Res Treat; 2012 Feb; 131(3):777-89. PubMed ID: 21452019
[TBL] [Abstract][Full Text] [Related]
6. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest.
Fan J; Lou B; Chen W; Zhang J; Lin S; Lv FF; Chen Y
Tumour Biol; 2014 Nov; 35(11):11523-32. PubMed ID: 25129440
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
[TBL] [Abstract][Full Text] [Related]
10. Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells.
Haydn T; Metzger E; Schuele R; Fulda S
Cell Death Dis; 2017 Jun; 8(6):e2879. PubMed ID: 28617441
[TBL] [Abstract][Full Text] [Related]
11. LSD1 coordinates with the SIN3A/HDAC complex and maintains sensitivity to chemotherapy in breast cancer.
Yang Y; Huang W; Qiu R; Liu R; Zeng Y; Gao J; Zheng Y; Hou Y; Wang S; Yu W; Leng S; Feng D; Wang Y
J Mol Cell Biol; 2018 Aug; 10(4):285-301. PubMed ID: 29741645
[TBL] [Abstract][Full Text] [Related]
12. Histone Demethylase LSD1 Inhibitors Prevent Cell Growth by Regulating Gene Expression in Esophageal Squamous Cell Carcinoma Cells.
Hoshino I; Akutsu Y; Murakami K; Akanuma N; Isozaki Y; Maruyama T; Toyozumi T; Matsumoto Y; Suito H; Takahashi M; Sekino N; Komatsu A; Suzuki T; Matsubara H
Ann Surg Oncol; 2016 Jan; 23(1):312-20. PubMed ID: 25791791
[TBL] [Abstract][Full Text] [Related]
13. Interference of lysine-specific demethylase 1 inhibits cellular invasion and proliferation in vivo in gastric cancer MKN-28 cells.
Li Y; Tian X; Sui CG; Jiang YH; Liu YP; Meng FD
Biomed Pharmacother; 2016 Aug; 82():498-508. PubMed ID: 27470390
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.
Singh MM; Manton CA; Bhat KP; Tsai WW; Aldape K; Barton MC; Chandra J
Neuro Oncol; 2011 Aug; 13(8):894-903. PubMed ID: 21653597
[TBL] [Abstract][Full Text] [Related]
15. HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer.
Li A; Liu Z; Li M; Zhou S; Xu Y; Xiao Y; Yang W
Oncotarget; 2016 Jun; 7(25):37966-37978. PubMed ID: 27177225
[TBL] [Abstract][Full Text] [Related]
16. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
[TBL] [Abstract][Full Text] [Related]
17. The Effects of Combinatorial Genistein and Sulforaphane in Breast Tumor Inhibition: Role in Epigenetic Regulation.
Paul B; Li Y; Tollefsbol TO
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29899271
[TBL] [Abstract][Full Text] [Related]
18. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells.
Fiskus W; Sharma S; Shah B; Portier BP; Devaraj SG; Liu K; Iyer SP; Bearss D; Bhalla KN
Leukemia; 2014 Nov; 28(11):2155-64. PubMed ID: 24699304
[TBL] [Abstract][Full Text] [Related]
19. Novel combination of histone methylation modulators with therapeutic synergy against acute myeloid leukemia in vitro and in vivo.
Wen S; Wang J; Liu P; Li Y; Lu W; Hu Y; Liu J; He Z; Huang P
Cancer Lett; 2018 Jan; 413():35-45. PubMed ID: 29069576
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
Lapierre M; Linares A; Dalvai M; Duraffourd C; Bonnet S; Boulahtouf A; Rodriguez C; Jalaguier S; Assou S; Orsetti B; Balaguer P; Maudelonde T; Blache P; Bystricky K; Boulle N; Cavaillès V
Oncotarget; 2016 Apr; 7(15):19693-708. PubMed ID: 26930713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
